|
孙昊, 吴昊, 栾春业. 缺血性脑卒中相关危险因素的病例对照研究 [J]. 实用临床医药杂志, 2010(1):32.doi: 10.3969/j.issn.1672-2353.2010.01.010.
|
|
蔡建华, 秦亚玲. 抗血小板聚集药在缺血性脑卒中的应用 [J]. 医学综述, 2012(1):139.doi: 10.3969/j.issn.1006-2084.2012.01.049.
|
|
Gasparyan A Y, Watson T, Lip G Y. The role of aspirin in cardiovascular prevention:implications of aspirin resistance [J]. Journal of the American College of Cardiology, 2008, (19):1829.
|
|
Quinn T J, Paolucci S, Sunnerhagen K S. Evidence-based stroke r-ehabilitation:an expanded guidance document from the european stroke organisation (ESO) guidelines for management of ischaemic stroke and transient ischaemic attack 2008 [J]. JOURNAL OF REHABILITATION MEDICINE, 2009(2):99.
|
|
Adams R J, Albers G, Alberts M J. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack [J]. Stroke, 2008(5):1647.
|
|
Kohyama K, Hashimoto M, Abe S. Thromboxane A2 receptor + 795T》C and chemoattractant receptor-homologous molecule expressed on Th2 cells-466T》C gene polymorphisms in patients with aspirin-exacerbated respiratory disease [J]. Mol Med Report, 2012(2):477.
|
|
Zhang C, Sun A, Zhang P. Aspirin for primary prevention of cardiovascular events in patients with diabetes:A meta-analysis [J]. Diabetes Research and Clinical Practice, 2010(2):211.
|
|
Dalen J E. Aspirin to prevent heart attack and stroke:what's the right dose [J]. American Journal of Medicine, 2006(3):198.
|
|
Hennekens CH. Aspirin in the treatment and prevention of cardiovascular disease:current perspectives and future directions [J]. Current Atherosclerosis Report, 2007(5):409.
|
|
Hennekens C H, Schneider W R. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease [J]. Expert Rev Cardiovase Ther, 2008(1):95.
|
|
Guthrie R. Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events [J]. Advances in Therapy, 2011(6):473.
|
|
Alvarez-Sabín J, Penalba A, Quintana M. Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke [J]. Cerebrovascular Diseases, 2009(4):371.
|
|
Whitehead SN, Bayona NA, Cheng G. Effects of triflusal and aspirin in a rat model of cerebral ischemia [J]. Stroke, 2007(2):381.
|
|
Gorelick PB, Richardson D, Kelly M. Aspirin and ticlopidine for prevention of recurrent stroke in black patients:a randomized trial [J]. Journal of the American Medical Association, 2003, (22):2947.
|
|
Shulga O, Bornstein N. Antiplatelets in secondary stroke prevention [J]. Front Neurol, 2011.36.
|
|
Wong KS, Chen C, Fu J. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study):a randomised, open-label, blinded-endpoint trial [J]. Lancet Neuro, 2010(5):489.
|
|
Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L. Aspirin in the primary and secondary prevention of vascular disease:collaborative meta-analysis of individual participant data from randomised trials [J]. The Lancet, 2009, (9678):1849.
|
|
Halkes PH, Gray L J, Bath PM. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke:a meta-analysis by risk [J]. Journal of Neurology, Neurosurgery & Psychiatry, 2008, (11):1218.
|
|
Weinberger J. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT):randomised controlled trial [J]. Current Cardiology Reports, 2007(1):5.
|
|
Diener HC, Sacco RL, Yusuf S. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRo-FESS) trial:a double-blind, active and placebo-controlled study [J]. Lancet Neurology, 2008, (10):875.
|
|
Shinohara Y, Katayama Y, Uchiyama S. Cilostazol for prevention of secondary stroke (CSPS 2):an aspirin-controlled, double blind, randomised non-inferiority trial [J]. Lancet Neurology, 2010, (10):959.
|
|
Huang Y, Cheng Y, Wu J. Cilostazol as an alternative to aspirin after ischaemic stroke:a randomised, double-blind, pilot study [J]. Lancet Neurology, 2008(6):494.
|
|
Stead LG, Vaidyanathan L. Evidence-based emergency medicine/systematic review abstract.Role of abciximab in the management of acute ischemic stroke [J]. Annals of Emergency Medicine, 2009(3):392.
|
|
Saltzman AJ, Mehran R, Hooper WC. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention [J]. Journal of Invasive Cardiology, 2010(1):2.
|
|
Desch S, Siegemund A, Scholz U. Platelet inhibition and GP Ⅱb/Ⅲa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction [J]. CLINICAL RESEARCH IN CARDIOLOGY, 2012(2):117.
|
下载:
苏公网安备 32100302010246号